Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 1.00 |
| ▸ | CNR1 | P21554 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584424 | 0.94 | CNR2 (0.88) | CNR2CNR1KCNH2 | |
| SCHEMBL585586 | 0.93 | CNR2 (0.88) | CNR2CNR1KCNH2 | |
| SCHEMBL584109 | 0.91 | CNR2 (1.00) | CNR2CNR1KCNH2 | |
| SCHEMBL585484 | 0.90 | CNR2 (0.84) | CNR2CNR1KCNH2 | |
| SCHEMBL589193 | 0.90 | CNR2 (0.82) | CNR2CNR1KCNH2 | |
| SCHEMBL584127 | 0.88 | CNR2 (0.79) | CNR2CNR1KCNH2 | |
| SCHEMBL3927831 | 0.88 | CNR2 (0.79) | CNR2CNR1KCNH2 | |
| SCHEMBL583992 | 0.86 | CNR2 (0.76) | CNR2CNR1KCNH2 | |
| SCHEMBL585474 | 0.84 | CNR2 (0.73) | CNR2CNR1KCNH2 | |
| SCHEMBL3920260 | 0.83 | CNR2 (0.73) | CNR2CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | claimed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | claimed |
| CN-119497589-A | Therapeutic combinations, compositions and methods for designing and producing conditions that promote mental well-being | 心境设计实验室股份有限公司 | 2025-02-21 | — | — | CN | claimed |
| WO-2023237875-A1 | PLURALITY OF GRANULES | Artelo Biosciences Limited (GB) | 2023-12-14 | — | — | WO | claimed |
| EP-4259111-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST | Artello Biosciences Limited (GB) | 2023-10-18 | — | — | EP | claimed |
| CN-116528842-A | Pharmaceutical composition comprising a cannabinoid agonist | 阿尔特洛生物科学有限公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2022123233-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST | Artelo Biosciences Limited (GB) | 2022-06-16 | — | — | WO | claimed |
| US-20100022610-A1 | New Crystalline Forms | BOHLIN MARTIN | 2010-01-28 | — | — | US | claimed |
| US-7566788-B2 | Crystalline forms | ASTRAZENECA AB (SE) | 2009-07-28 | — | — | US | claimed |
| EP-2001856-A1 | CRYSTALLINE FORMS OF N- {2-TERT -BUTYL -1- [ (4,4- DIF LUOROCYCLOHEXYL) METHYL]-LH-BENZIMIDAZOL-5- YL}ETHANESULFONAMIDE SALTS | AstraZeneca AB (SE) | 2008-12-17 | — | — | EP | claimed |
| WO-2007108754-A1 | CRYSTALLINE FORMS OF N- {2-TERT -BUTYL -1- [ (4,4- DIF LUOROCYCLOHEXYL) METHYL] -LH-BENZIMIDAZOL-5- YL}ETHANESULFONAMIDE SALTS | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | claimed |
| US-20070225346-A1 | Crystalline Forms | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | claimed |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025052179-A1 | CANNABINOID FOR USE IN TREATING EYE DISORDERS | Artelo Biosciences Limited (GB) | 2025-03-13 | — | — | WO | disclosed |
| WO-2007108754-A1 | CRYSTALLINE FORMS OF N- {2-TERT -BUTYL -1- [ (4,4- DIF LUOROCYCLOHEXYL) METHYL] -LH-BENZIMIDAZOL-5- YL}ETHANESULFONAMIDE SALTS | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007108754-A1 | CRYSTALLINE FORMS OF N- {2-TERT -BUTYL -1- [ (4,4- DIF LUOROCYCLOHEXYL) METHYL] -LH-BENZIMIDAZOL-5- YL}ETHANESULFONAMIDE SALTS | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007108754-A1 | CRYSTALLINE FORMS OF N- {2-TERT -BUTYL -1- [ (4,4- DIF LUOROCYCLOHEXYL) METHYL] -LH-BENZIMIDAZOL-5- YL}ETHANESULFONAMIDE SALTS | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | disclosed |
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | CNR2 83/4885CNR1 54/4885KCNH2 397/4885 |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | CNR2 1/4885CNR1 2/4885KCNH2 4284/4885 |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | CNR2 1/4885CNR1 2/4885KCNH2 396/4885 |
| US-20100022610-A1 | New Crystalline Forms | ME1, TST, FH | CNR2 4419/4885CNR1 4422/4885KCNH2 2472/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | CNR2 1/4885CNR1 2/4885KCNH2 2779/4885 |
| US-20070225346-A1 | Crystalline Forms | TST, ME1, FH | CNR2 4386/4885CNR1 4362/4885KCNH2 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.